Hori, Akiyo Sahashi, Haruka Sano, Sora Matsumiya, Emiri Ariga, Maho Asano, Akari Soda, Midori Goto, Chitoshi Mizui, Takashi Komeda, Hisao
...
Published in
Anticancer research
It has been reported that some adverse events (AEs) of enzalutamide (ENZ) occur more frequently in Japanese patients with castration-resistant prostate cancer (CRPC) due to higher steady-state trough plasma concentrations of ENZ (CSS, ENZ) and its active metabolite (NDE), (CSS, NDE). Thus, we investigated the efficacy, safety, and pharmacokinetics ...
Vellky, Jordan E McSweeney, Sean T Ricke, Emily A Ricke, William A
Published in
Proceedings of the National Academy of Sciences of the United States of America
Prostate cancer (CaP) driven by androgen receptor (AR) is treated with androgen deprivation; however, therapy failure results in lethal castration-resistant prostate cancer (CRPC). AR-low/negative (ARL/-) CRPC subtypes have recently been characterized and cannot be targeted by hormonal therapies, resulting in poor prognosis. RNA-binding protein (RB...
España, Sofia Ochoa de Olza, Maria Sala, Nuria Piulats, Josep Maria Ferrandiz, Ulises Etxaniz, Olatz Heras, Lucia Buisan, Oscar Pardo, Juan Carlos Suarez, Jose F
...
Published in
Cancer Management and Research
Background Abiraterone acetate (AA) is widely used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage of patients will still progress, highlighting the need to identify patients more likely to benefit from AA. Parameters linked to prostate-specific antigen (PSA) kinetics are ...
Messner, Elisabeth A Steele, Thomas M Tsamouri, Maria Malvina Hejazi, Nazila Gao, Allen C Mudryj, Maria Ghosh, Paramita M
The androgen receptor (AR) plays a predominant role in prostate cancer (PCa) pathology. It consists of an N-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region (HR), and a ligand-binding domain (LBD) that binds androgens, including testosterone (T) and dihydrotestosterone (DHT). Ligand binding at the LBD promotes AR dimerization and t...
Uo, Takuma Sprenger, Cynthia C. Plymate, Stephen R.
Published in
Frontiers in Oncology
Metabolic reprogramming is associated with re/activation and antagonism of androgen receptor (AR) signaling that drives prostate cancer (PCa) progression to castration resistance, respectively. In particular, AR signaling influences the fates of citrate that uniquely characterizes normal and malignant prostatic metabolism (i.e., mitochondrial expor...
Obinata, Daisuke Lawrence, Mitchell G Takayama, Kenichi Choo, Nicholas Risbridger, Gail P Takahashi, Satoru Inoue, Satoshi
Published in
Frontiers in oncology
The androgen receptor (AR) is the main therapeutic target in advanced prostate cancer, because it regulates the growth and progression of prostate cancer cells. Patients may undergo multiple lines of AR-directed treatments, including androgen-deprivation therapy, AR signaling inhibitors (abiraterone acetate, enzalutamide, apalutamide, or darolutami...
Ye, Senlin Wang, Haohui He, Kancheng Peng, Mou Wang, Yinhuai Li, Yuanwei Jiang, Shusuan Li, Jin Yi, Lu Cui, Rongrong
...
Published in
Frontiers in Oncology
Mismatch repair-deficient (dMMR) prostate cancer is rare and has not been well studied. We aimed to evaluate the clinical characterization of dMMR metastatic castration-resistant prostate cancer (mCRPC) patients. The MMR genes include MLH1, MLH3, MSH2, MSH6, PMS1, PMS2, and EPCAM, and were analyzed by targeted sequencing of plasma cell-free DNA sam...
Drápela, Stanislav Khirsariya, Prashant van Weerden, Wytske M Fedr, Radek Suchánková, Tereza Búzová, Diana Červený, Jan Hampl, Aleš Puhr, Martin Watson, William R
...
Published in
Molecular oncology
As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and contro...
Li, Zhoulei He, Peng Luo, Ganhua Shi, Xinchong Yuan, Gang Zhang, Bing Seidl, Christof Gewies, Andreas Wang, Yue Zou, Yuan
...
Published in
Frontiers in Pharmacology
Background The anticancer potential of pharmacologic ascorbic acid (AA) has been detected in a number of cancer cells. However, in vivo study suggested a strongly reduced cytotoxic activity of AA. It was known that pH could be a critical influencing factor for multiple anticancer treatments. In this study, we explored the influence of pH on the cyt...
Chen, Yanhua Li, Xin Mamouni, Kenza Yang, Yang Danaher, Alira White, Joseph Liu, HongYan Kucuk, Omer Gera, Lajos Wu, Daqing
...
Published in
The Prostate
Androgen deprivation therapy (ADT) is the mainstay of treatment for castration-resistant prostate cancer (CRPC). Unfortunately, although ADT initially prolongs survival, most patients relapse and develop resistance. Clinical failure of these treatments in CRPC highlights the urgent need to develop novel strategies to more effectively block androgen...
